Shares of MoonLake Immunotherapeutics (MLTX) gained over 15% on Tuesday morning driven by a report that Merck (MRK) has offered to buy it for "more than $3 billion."
MLTX is currently trading at $47.53, up $6.37 or 15.48%, on the Nasdaq. The stock opened its trading at $47.82 after closing Monday at $41.16. The stock has traded between $31.42 and $58.26 in the past 52-week period.
According to Financial Times, Merck has held talks to buy the Swiss biotech company for more than $3 billion.
Merck has submitted a nonbinding offer for MoonLake earlier this year, according to the report, which added that the initial approach was rejected but talks could be revived.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.